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OBJECTIVES The goal of this study was to analyze the incidence and predictors of postprocedure chest pain
(PPCP) after percutaneous coronary intervention (PCI) and its correlation with clinical
restenosis.
BACKGROUND Chest pain after PCI occurs frequently even in the absence of procedural events and is
considered to be due to vasospasm or coronary artery stretch. The short- and long-term
significance of PPCP after otherwise successful stenting is not clear.
METHODS We analyzed 1,362 patients undergoing coronary stenting for PPCP, procedural and
in-hospital events, 30-day major adverse cardiac events, and target vessel revascularization
(TVR) at 6 to 9 months.
RESULTS There were 488 patients with PPCP and, of these, 312 patients were excluded due to
procedural events. The remaining 176 patients with PPCP were compared with 874 patients
without PPCP. Creatine kinase-MB isoenzyme elevation occurred in 25.6% of the PPCP
group versus 9.6% of the no PPCP group (p  0.001). Despite similar reference vessel
diameter, the PPCP group had larger postprocedure minimum lumen diameter, higher
stent-to-vessel ratio, and higher inflation pressure versus the no PPCP group (p  0.01). At
30 days, the emergency room visits and repeat catheterization (16% vs. 2.7%; p 0.001) were
higher in the PPCP group versus the no PPCP group, but repeat intervention was similar. At
6- to 9-month follow-up, the TVR was significantly higher in the PPCP group compared
with the no PPCP group (29.5% vs. 16.6%; p  0.01).
CONCLUSIONS Our analysis suggests micromyonecrosis and vessel stretch as causes of PPCP. Postprocedure
chest pain is associated with similar short-term outcome as no PPCP, but has higher
restenosis, perhaps mediated by deep vessel wall injury. Therefore, PPCP may identify
patients at high risk for restenosis. (J Am Coll Cardiol 2003;41:33–8) © 2003 by the
American College of Cardiology Foundation
Postprocedure chest pain (PPCP) after percutaneous coro-
nary intervention (PCI) occurs frequently and is usually
related to procedural events (1–3). Several reports have
suggested that the PPCP is most likely due to various
procedural events, such as abrupt vessel closure, coronary
vasospasm, side-branch closure, dissection, distal thrombo-
embolism, slow-flow, focal vessel stretch, or adventitial
injury, which often occur with newer devices such as
atherectomy and stenting (1–8). Many of these patients
undergo early angiography (sometimes in-hospital) to rule
out acute closure frequently associated with creatine
kinase-MB isoenzyme (CK-MB) elevation (1–3). The use
of glycoprotein IIb/IIIa inhibitors (GPI) during PCI has
been shown to reduce periprocedural enzyme elevation,
perhaps by decreasing platelet-mediated distal microthrom-
boembolism, an inherent part of PCI (9,10). However, in
the absence of procedural events, PPCP is considered
benign and postulated to be due to local vessel stretch and
deep adventitial injury, especially in patients undergoing
stenting (2,5). There have been reports suggesting a higher
incidence of intimal hyperplasia or periprocedural enzyme
release after stent implantation using high-pressure deploy-
ment and/or higher stent-to-vessel size ratio (11–13). This
may be mediated via deep vessel wall (adventitial) injury
causing aggressive intimal hyperplasia and subsequent reste-
nosis (12). With the current practice of moderate- to
high-pressure stent deployment, the clinical implication of
PPCP without any obvious procedural complications is not
well understood. We analyzed patients undergoing coronary
stenting in relation to the presence or absence of PPCP and
correlated with periprocedural enzyme release, short-term
outcome, and need for target vessel revascularization
(TVR).
METHODS
Patients. All consecutive patients undergoing coronary
stenting of native coronary artery at Mount Sinai Hospital,
New York, from July 1999 to July 2000, were analyzed.
Patients with acute myocardial infarction (MI) (n  162)
and elevated preprocedural CK-MB, troponin I (TnI), or
ongoing chest pain (n  306) were excluded. Also, patients
with planned staged intervention (n  312) and lost for
follow-up (n  22) were excluded. A total of 1,362
consecutive nonacute MI patients undergoing stenting were
analyzed, of which 488 (35.8%) had PPCP or some proce-
dural event, and 874 (64.2%) had no PPCP with no
procedural event. In the PPCP or procedural event group,
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312 (63.9%) patients had some procedural events (94% also
had PPCP) and were analyzed as the procedural event
registry patients, while the remaining 176 patients with
PPCP and no procedural events (12.9% from entire group)
comprised the study population. These 176 patients with
PPCP and no procedural complications were compared
with 874 patients with no PPCP and no procedural event.
A 12-lead electrocardiogram (ECG) was done on all pa-
tients pre-, post-, and morning after procedure, and as
frequently as needed clinically in the presence of PPCP.
Cardiac enzymes (CK-MB, TnI) were measured at baseline,
preprocedure, 6 to 8 h, and 12 to 24 h after procedure, and
thereafter if still rising. All patients were routinely ques-
tioned for presence or absence of chest pain after procedure
and the next morning by an independent nurse practitioner
(14). Chest pain severity was graded from 1 to 10, 10 being
the worst. Patients were followed for in-hospital major
adverse cardiac events (MACE). All procedural details,
postprocedural events, and in-hospital events were captured
on an angioplasty worksheet and transferred to the inter-
ventional database. All angiograms were carefully analyzed
to identify any procedural events, especially side-branch
closure of 1.0-mm size. All patients had 30-day and 6- to
9-month clinical follow-up by a telephone call to the patient
or private physician. All interventions were done using a
conventional technique, using aspirin 325 mg daily pre- and
postprocedure indefinitely, clopidogrel 300 mg loading pre-
procedure and 75 mg daily for one month after PCI, and
low-dose heparin (70 IU/kg) to keep the activated clotting
time at approximately 250 s. The types of stent used were
Multilink (Guidant Corp., Indianapolis, Indiana), Duet
(Guidant Corp.), or Tetra (Guidant Corp.) in 55% of cases,
NIR (Boston Scientific/Scimed, Maple Grove, Minnesota)
in 35%, and S660 or S670 (Medtronic Inc., Minneapolis,
Minnesota) in 20% of cases. A single experienced individual
who was unaware of the purpose and outcome of the study
independently performed quantitative angiographic analysis
on the CMS Medis system (The Netherlands).
Definitions. Postprocedure chest pain was defined as vary-
ing degrees of typical or atypical chest pain starting after
PCI. Creatine kinase-MB isoenzyme measured by the Mass
technique was considered normal if 16 U/l and elevated if
16 U/l further subdivided in 1 to 3  (16 to 48 U/l), 3 to
5  (49 to 80 U/l), and 5 (81 U/l) normal. Troponin I
of 2.0 ng/ml was considered elevated. Significant ECG
changes were ST-segment depression 1.0 mm or any
ST-segment elevation. Nonspecific ECG changes were
ST-segment depression 1.0 mm or T-wave changes.
Procedural events were defined as transient or persistent
acute closure, coronary vasospasm, side-branch occlusion of
1.0-mm size, coronary dissection type C, thromboembo-
lism or air embolism, slow-flow or no flow, perforation,
and/or prolonged hypotension. Stent-to-vessel ratio was
calculated by dividing the nominal size of the maximum
final stent or postdilation balloon to the reference vessel size.
Angiographic lesion morphology was classified in the usual
manner, including complex/thrombotic (irregular, ulcer-
ated, haziness, or visible filling defect), calcified, and Amer-
ican College of Cardiology/American Heart Association
(ACC/AHA) classification. Major adverse cardiac events
were defined as death, Q-wave MI or large non–Q-wave
MI with CK-MB8 normal, or urgent revascularization.
Statistics. Data were entered in the interventional database
(Access-based program), and the required data retrieved in
Microsoft Excel format and transferred to the statistical
program for analysis. Pearson’s chi-squared test was used for
analysis of cross-tabulation of the categorical variables.
Fisher exact test was used for 2  2 cross-table analysis.
Student t test was used for continuous variables. Continuous
variables were presented as mean  SD. Stepwise logistic
regression technique (forward logistic regression method)
was employed to obtain multivariate predictors for resteno-
sis (entry probability 0.05; removal probability 0.20). All
analysis was performed using SAS/JMP (SAS Institute,
Cary, North Carolina) and SPSS 10.0 (SPSS Inc., Chicago,
Illinois). A p value of 0.05 was considered statistically
significant.
RESULTS
Baseline characteristics. Baseline clinical and procedural
characteristics are shown in Table 1. There was a signifi-
cantly higher incidence of females, patients with rest angina
or post-MI, and GPI use in the PPCP versus no PPCP
groups. Angiographic and quantitative coronary angio-
graphic data are shown in Table 2. Patients with PPCP
were more likely to have left anterior descending coronary
artery (LAD), complex thrombotic lesions, and more severe
stenosis. The PPCP group had similar reference vessel size,
but higher postprocedure minimum lumen diameter
(MLD), need for postdilation, less debulking, and higher
inflation pressure (16 atm) versus the no PPCP group.
Nature and evaluation of PPCP. In 92% of patients,
PPCP was predominantly at rest. In 68% of patients, PPCP
Abbreviations and Acronyms
ACC/AHA  American College of
Cardiology/American Heart Association
CI  confidence interval
CK-MB  creatine kinase-MB isoenzyme
ECG  electrocardiogram
GPI  glycoprotein IIb/IIIa inhibitors
LAD  left anterior descending coronary artery
MACE  major adverse cardiac events
MI  myocardial infarction
MLD  minimum lumen diameter
OR  odds ratio
PCI  percutaneous coronary intervention
PPCP  postprocedure chest pain
TnI  troponin I
TVR  target vessel revascularization
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was not similar to preprocedure anginal pain. In 54% of
patients, PPCP was continuous dull aching with fluctuation
in severity. The PPCP severity grades varied from 1 to 7
(average 4). In 96% of patients, PPCP started within 24 h
of PCI. In 47% of the patients who had PPCP, the pain
lasted for nearly 24 h (mean, 14.12  10.21 h) after
procedure, 35% had pain up to 72 h, and minority had pain
up to 14 days (Fig. 1). Nonspecific ECG changes were seen
in 11.4% of the PPCP patients, but no patient had signif-
icant ECG changes. The average length of stay was 3.1 
1.2 days versus 2.1 1.6 days in the PPCP versus no PPCP
groups (p  0.07).
PPCP and enzyme elevation. In the PPCP group, any
CK-MB elevation (Fig. 2) was seen in 25.6% versus 9.6% in
the no PPCP group (p  0.001). Similarly, TnI elevation
was seen in 55.7% versus 15.4% in the PPCP and no PPCP
groups, respectively (p  0.001). Multivariate predictors of
CK-MB elevation, excluding PPCP, were acute coronary
syndrome (odds ratio [OR], 4.2; 95% confidence interval
[CI], 2.5 to 6.6), stent-to-vessel ratio 1.1 (OR, 1.5; 95%
CI, 1.1 to 2.2), inflation pressure 16 atm (OR, 3.5; 95%
CI, 1.3 to 6.2), thrombotic lesion (OR, 7.5; 95% CI, 2.5 to
14.2), age (OR, 1.8; 95% CI, 1.3 to 2.2), and ACC/AHA
type C lesion (OR, 3.9; 95% CI, 2.2 to 5.8). In the PPCP
group, there were no differences in inflation pressure and
stent-to-vessel ratio between patients with or without
CK-MB elevation.
Multivariate predictors of PPCP were acute coronary
syndrome (OR, 4.6; 95% CI, 3.1 to 6.3), stent-to-vessel
ratio 1.1 (OR, 3.3; 95% CI, 2.4 to 5.1), inflation pressure
Table 1. Baseline Clinical and Short-Term Characteristics in the PPCP Versus No
PPCP Groups
Variables
PPCP Group
(n  176)
No PPCP Group
(n  874) p Value
Age (yrs) 62.3  9.4 64.2  9.1 NS
Female gender (%) 27.3 20.0 0.03
Rest angina (%) 32.3 21.3 0.001
Post-MI (%) 40.9 12.8 0.001
Hypertension (%) 40.1 42.2 0.65
Diabetes mellitus (%) 22.2 23.3 0.56
Hyperlipidemia (%) 52.3 51.6 0.55
LVEF (%) 45  12 46  12 0.72
GP IIb/IIIa use (%) 81.8 74.8 0.05
Multivessel intervention (%) 8.5 10.2 0.62
Multilesion intervention (%) 21.3 19.4 0.55
Activated clotting time (s) 252  62 248  48 0.33
In-hospital MACE (%) 0.6 0.4 0.52
In-hospital repeat angiography (%) 9.1 0.6  0.001
30-day events
Repeat angiography (%) 16.0 2.7  0.001
Repeat intervention (%) 2.3 1.9 0.44
MACE (%) 2.8 2.2 0.43
GP  glycoprotein; LVEF  left ventricular ejection fraction; MACE  major adverse cardiac events (death, Q-wave or large
non–Q-wave, MI, or urgent revascularization); MI  myocardial infarction; PPCP  postprocedure chest pain.
Table 2. Angiographic Characteristics and Quantitative Coronary Angiography Results in the
PPCP Versus no PPCP Groups
Variables
PPCP Group
(n  176)
No PPCP Group
(n  874) p Value
LAD lesion (%) 52.3 43.1 0.03
ACC/AHA type B2/C (%) 58/30 65/24 0.32
Lesion length (mm) 12.3  6.4 11.8  6.3 0.23
Moderate-heavy calcification (%) 28.4 22.5 0.09
Complex/thrombotic lesion (%) 14.8 6.2  0.001
Collateral grade 2 (%) 8.5 6.8 0.44
Direct stenting (%) 6.2 5.3 0.64
Postdilation (%) 18.7 8.6  0.01
Debulking (%) 15.3 24.9  0.01
Inflation pressure (%) 16  3 13  2  0.01
Stent length (mm) 16.2  8.2 16.8  7.6 0.24
Stent:vessel ratio 1.21  0.12 1.08  0.08 0.02
Reference vessel size (mm) 2.83  0.38 2.82  0.41 0.43
MLD, pre (mm) 0.68  0.21 0.82  0.23 0.05
MLD, post (mm) 2.73  0.42 2.45  0.32 0.01
ACC/AHA  American College of Cardiology/American Heart Association; LAD  left anterior descending coronary artery;
MLD  minimum lumen diameter; PPCP  postprocedure chest pain.
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16 atm (OR, 2.8; 95% CI, 1.4 to 4.7), and LAD lesion
(OR, 1.8; 95% CI, 1.2 to 2.6).
Clinical follow-up. At 30 days, the number of emergency
room visits (9.1% vs. 1.4%; p 0.001), readmissions (23.9%
vs. 3.0%; p  0.001), and repeat angiography (16.0% vs.
2.7%; p 0.001) were higher in the PPCP group versus the
no PPCP group (Table 1). However, repeat intervention,
subacute thrombosis, death, re-MI, and 30-day MACE
were not different between the two groups. The incidence of
30-day MACE was 2.5% in the atypical PPCP versus 3.0%
in the typical anginal PPCP (p  0.16). Clinically driven
coronary angiography after 30 days occurred in 36% of the
PPCP patients and 32% of no PPCP patients (p  NS). At
7.4 1.2 months clinical follow-up, TVR was 29.5% in the
PPCP group versus 16.6% in the no PPCP group (p 
0.01). Among the PPCP patients, TVR was 22.2% in the
CK-MB elevation group compared with 32% in the no
CK-MB elevation group (p  0.20). For the entire group
(both PPCP and no PPCP), the incidence of TVR was
17.8% in the CK-MB elevation group versus 18.9% in the
no CK-MB elevation group (pNS). The incidence of MI
and mortality was not different between the two groups
(2.2% vs. 1.5%; p  0.20).
On multivariate analysis the predictors of TVR after
stenting were PPCP (OR, 3.2; 95% CI, 1.9 to 4.6), diabetes
mellitus (OR, 2.6; 95% CI, 1.5 to 3.8), and lesion length
10 mm (OR, 1.9; 95% CI, 1.2 to 2.8). Postprocedure
MLD was not predictive of TVR once PPCP was entered in
the multivariate model.
Procedural events registry. In 312 patients with some
procedural events, 94% also had PPCP with CK-MB
elevation of 69.9% (1 to 3  normal  37.8%, 3 to 5 
normal  22.8%, and 5  normal  9.3%) and TnI
elevation of 77.9%. In-hospital MACE and 30-day MACE
were 2.2% and 4.8%, respectively; p  0.02 versus the
PPCP or the no PPCP group. The incidence of repeat
angiography in-hospital or at 30 days was 5.1% and 11.5%
(lower than PPCP group, but higher than no PPCP group).
At 8.2  1.8 months clinical follow-up, the incidence of
death and MI was 6.7% (p  0.01 vs. PPCP or no PPCP
Figure 1. Duration of postprocedure chest pain after percutaneous coronary intervention.
Figure 2. Incidence and magnitude of creatine kinase-MB isoenzyme (CK-MB) and troponin I (TnI) elevation in the two groups. Solid bar 
postprocedure chest pain (PCPP) (n  176); open bar  no PCPP (n  874).
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group), and TVR was 18.9% (p  0.007 vs. PPCP and p 
0.32 vs. no PPCP).
DISCUSSION
This study reports for the first time the clinical implication
of PPCP, which is seen in 36% of the patients undergoing
PCI, and, in two-thirds of the cases, a procedural compli-
cation/event could be identified. In the remaining one-third
of patients with PPCP who had no identifiable procedural
events, the most likely cause could be vessel stretch and/or
micromyonecrosis. Previous studies suggested vessel stretch/
adventitial injury as a possible mechanism of PPCP, which
was also observed in our study as suggested by higher
stent-to-vessel ratio and postprocedure MLD in the PPCP
group (1–4).
Mechanism of PPCP and short-term events. Incidence
of periprocedural CK-MB elevation after PCI varies (10%
to 30%), mostly due to various procedural events including
distal embolization of plaque and thrombus, and side-
branch closure especially after stenting (6–8). To evaluate
the exact mechanism of periprocedural CK-MB elevation, a
recent report of contrast-enhanced magnetic resonance
imaging, before and after PCI, in nine patients revealed
side-branch closure in five of them (55%) and distal throm-
boembolism in four (45%) despite very high use of GPI (8).
Several studies have shown that chest pain after coronary
intervention correlates with procedural complications or
ongoing ischemia as reflected by elevated CK-MB (2,3,7).
In our study, the incidence of CK-MB and TnI elevation
after PCI in the PPCP group with no identifiable proce-
dural events was 25.6% and 55.7%, respectively, which we
hypothesized to be due to micromyonecrosis caused by
distal microthromboembolism. This hypothesis can be fur-
ther substantiated by the fact that more patients with acute
coronary syndrome and thrombotic lesions were seen in the
PPCP group and were likely to be at high-risk for distal
thromboembolism, despite a higher use of GPI. Markers of
vessel stretch (high inflation pressure, high stent-to-vessel
ratio) were higher in both CK-MB elevation and no
CK-MB elevation patients in the PPCP group. This may
implicate vessel stretch contributing to distal microemboli-
zation (13).
Stent implantation results in a larger postprocedure
MLD, causing a higher degree of circumferential stretching
resulting in irritation of sensory nerves located in adventitia
and, thereby, can cause PPCP (5). This adventitial irritation
can be a plausible explanation of PPCP in our study in
patients without any postprocedure enzyme elevation. Both
micromyonecrosis and vessel stretch contributed to the
development of PPCP, but the exact extent of contribution
of individual pathophysiologic process could not be estab-
lished with certainty in the present study. In the current
study, occurrence of PPCP in the absence of any obvious
procedural complications was benign at short-term (30
days), not associated with higher revascularization or isch-
emic complications, but at the cost of higher health care
resource utilization. Therefore, many times PPCP can be
distinguished from ongoing ischemic pain by its nature,
which is often atypical, continuous, and dull aching with
fluctuation in severity.
PPCP as a predictor of clinical restenosis. Larger final
MLD after various interventional devices has correlated
with lower restenosis based on the “bigger is better” hypoth-
esis (15). However, deep vessel wall injury, which may occur
in a subset of patients due to overexpansion of stent causing
adventitial irritation with resultant PPCP, has been shown
to subsequently cause intense inflammation and exaggerated
intimal hyperplasia by stent struts (11,12). This process of
aggressive intimal hyperplasia after stenting may explain the
higher incidence of TVR in the PPCP group in our study
and even offset the advantage of a larger final MLD, as the
final MLD was not associated with lower restenosis on
multivariate analysis in this study. Also, PPCP was the
strongest independent predictor of clinical restenosis (in
addition to diabetes and lesion length), while other tradi-
tional risk factors like rest angina, thrombotic lesion, LAD
location, and debulking were not predictors on multivariate
analysis. Another interesting observation is that the majority
of patients requiring follow-up angiography had clinical
restenosis in the PPCP group versus the no PPCP group,
perhaps due to more symptom recurrence.
Therefore, PPCP identifies a group of patients who are at
risk of developing periprocedural enzyme elevation despite
GPI use and no obvious procedural complications, but have
a high incidence of clinical restenosis. As previously be-
lieved, patients developing PPCP without procedural events
or significant ECG changes can be safely monitored with-
out a need for repeat coronary angiography during the initial
index hospitalization. Nevertheless, these patients need to
be closely followed for symptoms of early restenosis.
Procedural events registry analysis. Similar to earlier re-
ported observation, patients undergoing PCI complicated
by procedural events are associated with high short- and
long-term clinical events of death or MI compared with
patients without procedural events, but not associated with
a higher incidence of clinical restenosis (16). This could be
explained by restenosis being clinically silent in these pa-
tients, the majority of whom have suffered periprocedural
MI.
Study limitations. This is a nonrandomized study with
clinical follow-up, but no routine follow-up angiography.
Intravascular ultrasound was not routinely performed, which
could have added in understanding the mechanism and
probably confirmed the theory of “vessel stretch” in causing
PPCP.
Study implications. Although PPCP in the absence of
procedural events is not associated with short-term clinical
events, the present study identifies these patients as high-
risk for periprocedural enzyme elevation and clinical reste-
nosis. While full stent expansion and optimum stent de-
ployment have been shown to be important for late outcome
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(15), our data suggest that oversizing stents and very high
inflation pressures could be detrimental because of deep wall
injury, causing aggressive intimal hyperplasia and restenosis.
Therefore, modifying procedural factors likely to cause
PPCP such as high inflation pressure, oversize stents, and
using appropriate debulking may result in lower clinical
restenosis. This practice is now being routinely applied in
our cath lab.
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